AnaptysBio, Inc. Receives Milestone Payment from Merck & Co., Inc. for Successful Delivery of Candidate Antibodies for Therapeutic Use

(BUSINESS WIRE)--AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, announced today the successful completion of an optimization project for Merck & Co., Inc. as part of an agreement for the delivery of candidate antibodies for therapeutic use.

Back to news